ID   FAK1_HUMAN              Reviewed;        1052 AA.
AC   Q05397; B4E2N6; F5H4S4; J3QT16; Q14291; Q8IYN9; Q9UD85;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   12-OCT-2022, entry version 250.
DE   RecName: Full=Focal adhesion kinase 1 {ECO:0000305};
DE            Short=FADK 1;
DE            EC=2.7.10.2;
DE   AltName: Full=Focal adhesion kinase-related nonkinase;
DE            Short=FRNK;
DE   AltName: Full=Protein phosphatase 1 regulatory subunit 71;
DE            Short=PPP1R71;
DE   AltName: Full=Protein-tyrosine kinase 2;
DE   AltName: Full=p125FAK;
DE   AltName: Full=pp125FAK;
GN   Name=PTK2 {ECO:0000312|HGNC:HGNC:9611}; Synonyms=FAK, FAK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=T-cell;
RX   PubMed=7692878; DOI=10.1089/dna.1993.12.823;
RA   Whitney G.S., Chan P.Y., Blake J., Cosand W.L., Neubauer M.G., Aruffo A.,
RA   Kanner S.B.;
RT   "Human T and B lymphocytes express a structurally conserved focal adhesion
RT   kinase, pp125FAK.";
RL   DNA Cell Biol. 12:823-830(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8422239; DOI=10.1006/bbrc.1993.1022;
RA   Andre E., Becker-Andre M.;
RT   "Expression of an N-terminally truncated form of human focal adhesion
RT   kinase in brain.";
RL   Biochem. Biophys. Res. Commun. 190:140-147(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 7).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PROTEIN SEQUENCE OF 2-19; 192-199; 222-236; 243-252; 350-364; 414-419;
RP   468-476; 562-569; 674-690; 798-811; 832-838; 904-933; 963-981; 989-1000 AND
RP   1003-1042, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Osteosarcoma;
RA   Bienvenut W.V., Glen H., Brunton V.G., Frame M.C.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 552-602, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [8]
RP   FUNCTION, INTERACTION WITH NEDD9, AND MUTAGENESIS OF TYR-397.
RX   PubMed=9360983; DOI=10.1074/jbc.272.46.29083;
RA   Tachibana K., Urano T., Fujita H., Ohashi Y., Kamiguchi K., Iwata S.,
RA   Hirai H., Morimoto C.;
RT   "Tyrosine phosphorylation of Crk-associated substrates by focal adhesion
RT   kinase. A putative mechanism for the integrin-mediated tyrosine
RT   phosphorylation of Crk-associated substrates.";
RL   J. Biol. Chem. 272:29083-29090(1997).
RN   [9]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=9422762; DOI=10.1074/jbc.273.2.1003;
RA   Matsuya M., Sasaki H., Aoto H., Mitaka T., Nagura K., Ohba T., Ishino M.,
RA   Takahashi S., Suzuki R., Sasaki T.;
RT   "Cell adhesion kinase beta forms a complex with a new member, Hic-5, of
RT   proteins localized at focal adhesions.";
RL   J. Biol. Chem. 273:1003-1014(1998).
RN   [10]
RP   INTERACTION WITH TGFB1I1, AND MUTAGENESIS OF VAL-928 AND LEU-1034.
RX   PubMed=9756887; DOI=10.1074/jbc.273.41.26516;
RA   Fujita H., Kamiguchi K., Cho D., Shibanuma M., Morimoto C., Tachibana K.;
RT   "Interaction of Hic-5, A senescence-related protein, with focal adhesion
RT   kinase.";
RL   J. Biol. Chem. 273:26516-26521(1998).
RN   [11]
RP   FUNCTION IN PXN PHOSPHORYLATION; REGULATION OF CELL SHAPE AND MIGRATION,
RP   INTERACTION WITH EPHA2, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, DEPHOSPHORYLATION BY PTPN11, AND SUBCELLULAR LOCATION.
RX   PubMed=10655584; DOI=10.1038/35000008;
RA   Miao H., Burnett E., Kinch M., Simon E., Wang B.;
RT   "Activation of EphA2 kinase suppresses integrin function and causes focal-
RT   adhesion-kinase dephosphorylation.";
RL   Nat. Cell Biol. 2:62-69(2000).
RN   [12]
RP   FUNCTION IN CELL MIGRATION AND ACTIVATION OF BMX, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF TYR-397, AND INTERACTION WITH BMX.
RX   PubMed=11331870; DOI=10.1038/35074500;
RA   Chen R., Kim O., Li M., Xiong X., Guan J.L., Kung H.J., Chen H.,
RA   Shimizu Y., Qiu Y.;
RT   "Regulation of the PH-domain-containing tyrosine kinase Etk by focal
RT   adhesion kinase through the FERM domain.";
RL   Nat. Cell Biol. 3:439-444(2001).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF SHC1, AUTOPHOSPHORYLATION, INTERACTION WITH
RP   SHC1 AND SRC, AND ROLE IN DISEASE.
RX   PubMed=11980671;
RA   Hecker T.P., Grammer J.R., Gillespie G.Y., Stewart J. Jr., Gladson C.L.;
RT   "Focal adhesion kinase enhances signaling through the Shc/extracellular
RT   signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy
RT   samples.";
RL   Cancer Res. 62:2699-2707(2002).
RN   [14]
RP   INTERACTION WITH RB1CC1.
RX   PubMed=12221124; DOI=10.1091/mbc.e02-05-0295;
RA   Abbi S., Ueda H., Zheng C., Cooper L.A., Zhao J., Christopher R.,
RA   Guan J.L.;
RT   "Regulation of focal adhesion kinase by a novel protein inhibitor FIP200.";
RL   Mol. Biol. Cell 13:3178-3191(2002).
RN   [15]
RP   PHOSPHORYLATION AT TYR-397; TYR-407; TYR-577; TYR-861 AND TYR-925, AND
RP   INTERACTION WITH FGR.
RX   PubMed=12387730; DOI=10.1042/bj20020410;
RA   Relou I.A.M., Bax L.A.B., Van Rijn H.J.M., Akkerman J.-W.N.;
RT   "Site-specific phosphorylation of platelet focal adhesion kinase by low-
RT   density lipoprotein.";
RL   Biochem. J. 369:407-416(2003).
RN   [16]
RP   FUNCTION IN INTEGRIN SIGNALING; REGULATION OF APOPTOSIS; REGULATION OF CELL
RP   SHAPE AND ACTIVATION OF PHOSPHATIDYLINOSITOL KINASE AND AKT1 SIGNALING
RP   PATHWAY.
RX   PubMed=15166238; DOI=10.1074/jbc.m313265200;
RA   Xia H., Nho R.S., Kahm J., Kleidon J., Henke C.A.;
RT   "Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in
RT   regulating fibroblast survival in response to contraction of type I
RT   collagen matrices via a beta 1 integrin viability signaling pathway.";
RL   J. Biol. Chem. 279:33024-33034(2004).
RN   [17]
RP   FUNCTION IN REGULATION OF CELL MIGRATION, AND PHOSPHORYLATION AT TYR-407;
RP   TYR-397 AND TYR-576.
RX   PubMed=15561106; DOI=10.1016/j.yexcr.2004.09.005;
RA   Continolo S., Baruzzi A., Majeed M., Caveggion E., Fumagalli L.,
RA   Lowell C.A., Berton G.;
RT   "The proto-oncogene Fgr regulates cell migration and this requires its
RT   plasma membrane localization.";
RL   Exp. Cell Res. 302:253-269(2005).
RN   [18]
RP   INTERACTION WITH P53/TP53, AND SUBCELLULAR LOCATION.
RX   PubMed=15855171; DOI=10.1074/jbc.m414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase with
RT   the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [19]
RP   FUNCTION IN FOCAL ADHESION DISASSEMBLY.
RX   PubMed=15895076; DOI=10.1038/ncb1262;
RA   Ezratty E.J., Partridge M.A., Gundersen G.G.;
RT   "Microtubule-induced focal adhesion disassembly is mediated by dynamin and
RT   focal adhesion kinase.";
RL   Nat. Cell Biol. 7:581-590(2005).
RN   [20]
RP   INTERACTION WITH FLT4.
RX   PubMed=16452200; DOI=10.1158/0008-5472.can-05-1661;
RA   Garces C.A., Kurenova E.V., Golubovskaya V.M., Cance W.G.;
RT   "Vascular endothelial growth factor receptor-3 and focal adhesion kinase
RT   bind and suppress apoptosis in breast cancer cells.";
RL   Cancer Res. 66:1446-1454(2006).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [22]
RP   ALTERNATIVE PROMOTER USAGE, IDENTIFICATION OF ISOFORM 6, AND DEVELOPMENTAL
RP   STAGE (ISOFORM 6).
RX   PubMed=16998626; DOI=10.1007/s00795-006-0325-8;
RA   Nagoshi Y., Yamamoto G., Irie T., Tachikawa T.;
RT   "Expression of FAK-related non-kinase (FRNK) coincides with morphological
RT   change in the early stage of cell adhesion.";
RL   Med. Mol. Morphol. 39:154-160(2006).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [24]
RP   ACTIVITY REGULATION, ROLE IN DISEASE, AND PHOSPHORYLATION AT TYR-397 AND
RP   TYR-861.
RX   PubMed=18006843; DOI=10.1158/0008-5472.can-07-2667;
RA   Halder J., Lin Y.G., Merritt W.M., Spannuth W.A., Nick A.M., Honda T.,
RA   Kamat A.A., Han L.Y., Kim T.J., Lu C., Tari A.M., Bornmann W.,
RA   Fernandez A., Lopez-Berestein G., Sood A.K.;
RT   "Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in
RT   ovarian carcinoma.";
RL   Cancer Res. 67:10976-10983(2007).
RN   [25]
RP   FUNCTION, ACTIVITY REGULATION, ROLE IN DISEASE, AND PHOSPHORYLATION AT
RP   TYR-397.
RX   PubMed=17395594; DOI=10.1074/jbc.m606695200;
RA   Slack-Davis J.K., Martin K.H., Tilghman R.W., Iwanicki M., Ung E.J.,
RA   Autry C., Luzzio M.J., Cooper B., Kath J.C., Roberts W.G., Parsons J.T.;
RT   "Cellular characterization of a novel focal adhesion kinase inhibitor.";
RL   J. Biol. Chem. 282:14845-14852(2007).
RN   [26]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION.
RX   PubMed=16927379; DOI=10.1002/jcb.21074;
RA   Salasznyk R.M., Klees R.F., Boskey A., Plopper G.E.;
RT   "Activation of FAK is necessary for the osteogenic differentiation of human
RT   mesenchymal stem cells on laminin-5.";
RL   J. Cell. Biochem. 100:499-514(2007).
RN   [27]
RP   FUNCTION, ACTIVITY REGULATION, ROLE IN DISEASE, AND PHOSPHORYLATION AT
RP   TYR-397.
RX   PubMed=17431114; DOI=10.1158/1535-7163.mct-06-0476;
RA   Liu T.J., LaFortune T., Honda T., Ohmori O., Hatakeyama S., Meyer T.,
RA   Jackson D., de Groot J., Yung W.K.;
RT   "Inhibition of both focal adhesion kinase and insulin-like growth factor-I
RT   receptor kinase suppresses glioma proliferation in vitro and in vivo.";
RL   Mol. Cancer Ther. 6:1357-1367(2007).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH LPXN.
RX   PubMed=18497331; DOI=10.1161/circresaha.107.170357;
RA   Sundberg-Smith L.J., DiMichele L.A., Sayers R.L., Mack C.P., Taylor J.M.;
RT   "The LIM protein leupaxin is enriched in smooth muscle and functions as an
RT   serum response factor cofactor to induce smooth muscle cell gene
RT   transcription.";
RL   Circ. Res. 102:1502-1511(2008).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH BMX.
RX   PubMed=18292575; DOI=10.4049/jimmunol.180.5.3485;
RA   Semaan N., Alsaleh G., Gottenberg J.E., Wachsmann D., Sibilia J.;
RT   "Etk/BMX, a Btk family tyrosine kinase, and Mal contribute to the cross-
RT   talk between MyD88 and FAK pathways.";
RL   J. Immunol. 180:3485-3491(2008).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CASS4.
RX   PubMed=18256281; DOI=10.1091/mbc.e07-09-0953;
RA   Singh M.K., Dadke D., Nicolas E., Serebriiskii I.G., Apostolou S.,
RA   Canutescu A., Egleston B.L., Golemis E.A.;
RT   "A novel Cas family member, HEPL, regulates FAK and cell spreading.";
RL   Mol. Biol. Cell 19:1627-1636(2008).
RN   [31]
RP   FUNCTION IN REGULATION OF P53/TP53 LEVELS; CELL PROLIFERATION AND CELL
RP   SURVIVAL, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-enhanced
RT   p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [32]
RP   INTERACTION WITH ESR1; PIK3R1 AND/OR PIK3R2 AND SRC.
RX   PubMed=18657504; DOI=10.1016/j.molcel.2008.05.025;
RA   Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y., Sentis S.,
RA   Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S., Corbo L.;
RT   "Regulation of estrogen rapid signaling through arginine methylation by
RT   PRMT1.";
RL   Mol. Cell 31:212-221(2008).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-13; SER-29; SER-887 AND
RP   SER-910, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-910, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [36]
RP   PHOSPHORYLATION AT TYR-397; TYR-576; TYR-577; SER-722; TYR-861 AND TYR-925,
RP   AND IDENTIFICATION IN A COMPLEX WITH CTTN AND FER.
RX   PubMed=19339212; DOI=10.1016/j.bbamcr.2009.01.015;
RA   Oh M.A., Choi S., Lee M.J., Choi M.C., Lee S.A., Ko W., Cance W.G.,
RA   Oh E.S., Buday L., Kim S.H., Lee J.W.;
RT   "Specific tyrosine phosphorylation of focal adhesion kinase mediated by Fer
RT   tyrosine kinase in suspended hepatocytes.";
RL   Biochim. Biophys. Acta 1793:781-791(2009).
RN   [37]
RP   FUNCTION IN SRC-MEDIATED PHOSPHORYLATION OF PXN.
RX   PubMed=19138410; DOI=10.1186/1471-2407-9-12;
RA   Sachdev S., Bu Y., Gelman I.H.;
RT   "Paxillin-Y118 phosphorylation contributes to the control of Src-induced
RT   anchorage-independent growth by FAK and adhesion.";
RL   BMC Cancer 9:12-12(2009).
RN   [38]
RP   INTERACTION WITH STEAP4.
RX   PubMed=19787193; DOI=10.3892/ijmm_00000270;
RA   Tamura T., Chiba J.;
RT   "STEAP4 regulates focal adhesion kinase activation and CpG motifs within
RT   STEAP4 promoter region are frequently methylated in DU145, human androgen-
RT   independent prostate cancer cells.";
RL   Int. J. Mol. Med. 24:599-604(2009).
RN   [39]
RP   INTERACTION WITH EMP2.
RX   PubMed=19494199; DOI=10.1167/iovs.08-3315;
RA   Morales S.A., Mareninov S., Coulam P., Wadehra M., Goodglick L., Braun J.,
RA   Gordon L.K.;
RT   "Functional consequences of interactions between FAK and epithelial
RT   membrane protein 2 (EMP2).";
RL   Invest. Ophthalmol. Vis. Sci. 50:4949-4956(2009).
RN   [40]
RP   FUNCTION IN SRC-MEDIATED PHOSPHORYLATION OF BCAR1, AND ROLE IN DISEASE.
RX   PubMed=19147981; DOI=10.1172/jci37160;
RA   Pylayeva Y., Gillen K.M., Gerald W., Beggs H.E., Reichardt L.F.,
RA   Giancotti F.G.;
RT   "Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires
RT   focal adhesion kinase signaling.";
RL   J. Clin. Invest. 119:252-266(2009).
RN   [41]
RP   INTERACTION WITH EPHA1.
RX   PubMed=19118217; DOI=10.1242/jcs.036467;
RA   Yamazaki T., Masuda J., Omori T., Usui R., Akiyama H., Maru Y.;
RT   "EphA1 interacts with integrin-linked kinase and regulates cell morphology
RT   and motility.";
RL   J. Cell Sci. 122:243-255(2009).
RN   [42]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT TYR-5; THR-13; SER-29; TYR-397; TYR-570; SER-580 AND SER-910,
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [43]
RP   ROLE IN DISEASE, AND ACTIVITY REGULATION.
RX   PubMed=20495381; DOI=10.4161/cbt.10.1.11993;
RA   Sun H., Pisle S., Gardner E.R., Figg W.D.;
RT   "Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study
RT   in PC3M-luc-C6 local implant and metastasis xenograft models.";
RL   Cancer Biol. Ther. 10:38-43(2010).
RN   [44]
RP   INTERACTION WITH LPXN.
RX   PubMed=19917054; DOI=10.1111/j.1349-7006.2009.01398.x;
RA   Tanaka T., Moriwaki K., Murata S., Miyasaka M.;
RT   "LIM domain-containing adaptor, leupaxin, localizes in focal adhesion and
RT   suppresses the integrin-induced tyrosine phosphorylation of paxillin.";
RL   Cancer Sci. 101:363-368(2010).
RN   [45]
RP   FUNCTION (ISOFORM 6), AND TISSUE SPECIFICITY.
RX   PubMed=20109444; DOI=10.1016/j.yexcr.2010.01.021;
RA   Cai G.Q., Zheng A., Tang Q., White E.S., Chou C.F., Gladson C.L.,
RA   Olman M.A., Ding Q.;
RT   "Downregulation of FAK-related non-kinase mediates the migratory phenotype
RT   of human fibrotic lung fibroblasts.";
RL   Exp. Cell Res. 316:1600-1609(2010).
RN   [46]
RP   INTERACTION WITH ZFYVE21, AND DEPHOSPHORYLATION AT TYR-397.
RX   PubMed=20439989; DOI=10.1074/jbc.m110.106443;
RA   Nagano M., Hoshino D., Sakamoto T., Kawasaki N., Koshikawa N., Seiki M.;
RT   "ZF21 protein regulates cell adhesion and motility.";
RL   J. Biol. Chem. 285:21013-21022(2010).
RN   [47]
RP   INTERACTION WITH CD36.
RX   PubMed=20037584; DOI=10.1038/ni.1836;
RA   Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A.,
RA   Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A.,
RA   El Khoury J., Golenbock D.T., Moore K.J.;
RT   "CD36 ligands promote sterile inflammation through assembly of a Toll-like
RT   receptor 4 and 6 heterodimer.";
RL   Nat. Immunol. 11:155-161(2010).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-910 AND THR-914, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [50]
RP   INTERACTION WITH RET, FUNCTION IN RET PHOSPHORYLATION, AND PHOSPHORYLATION
RP   AT TYR-576 AND TYR-577.
RX   PubMed=21454698; DOI=10.1074/jbc.m110.168500;
RA   Plaza-Menacho I., Morandi A., Mologni L., Boender P.,
RA   Gambacorti-Passerini C., Magee A.I., Hofstra R.M.W., Knowles P.,
RA   McDonald N.Q., Isacke C.M.;
RT   "Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming
RT   a direct and reciprocal RET-FAK transactivation mechanism.";
RL   J. Biol. Chem. 286:17292-17302(2011).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-13; SER-29; SER-843 AND
RP   SER-910, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [52]
RP   INTERACTION WITH CIB1 ISOFORM 2.
RC   TISSUE=Brain;
RX   PubMed=23503467; DOI=10.1038/onc.2013.43;
RA   Armacki M., Joodi G., Nimmagadda S.C., de Kimpe L., Pusapati G.V.,
RA   Vandoninck S., Van Lint J., Illing A., Seufferlein T.;
RT   "A novel splice variant of calcium and integrin-binding protein 1 mediates
RT   protein kinase D2-stimulated tumour growth by regulating angiogenesis.";
RL   Oncogene 33:1167-1180(2014).
RN   [53]
RP   REVIEW ON SIGNALING AND ON DIRECT PTK2/FAK1 SUBSTRATES.
RX   PubMed=10354709; DOI=10.1016/s0079-6107(98)00052-2;
RA   Schlaepfer D.D., Hauck C.R., Sieg D.J.;
RT   "Signaling through focal adhesion kinase.";
RL   Prog. Biophys. Mol. Biol. 71:435-478(1999).
RN   [54]
RP   REVIEW ON FUNCTION IN NETRIN SIGNALING.
RX   PubMed=15725728;
RA   Nikolopoulos S.N., Giancotti F.G.;
RT   "Netrin-integrin signaling in epithelial morphogenesis, axon guidance and
RT   vascular patterning.";
RL   Cell Cycle 4:E131-E135(2005).
RN   [55]
RP   REVIEW ON FUNCTION IN CELL MIGRATION; FOCAL ADHESION TURNOVER AND
RP   ACTIVATION OF SIGNALING PATHWAYS, AND ROLE IN DISEASE.
RX   PubMed=16919435; DOI=10.1016/j.ceb.2006.08.011;
RA   Mitra S.K., Schlaepfer D.D.;
RT   "Integrin-regulated FAK-Src signaling in normal and cancer cells.";
RL   Curr. Opin. Cell Biol. 18:516-523(2006).
RN   [56]
RP   FUNCTION.
RX   PubMed=17968709; DOI=10.1080/15216540701694245;
RA   Vadali K., Cai X., Schaller M.D.;
RT   "Focal adhesion kinase: an essential kinase in the regulation of
RT   cardiovascular functions.";
RL   IUBMB Life 59:709-716(2007).
RN   [57]
RP   REVIEW ON ROLE IN INTEGRIN SIGNALING AND IN REGULATION OF P53/TP53
RP   ACTIVITIES, ROLE IN DISEASE, AND ACTIVITY REGULATION.
RX   PubMed=18677107; DOI=10.4161/cc.6367;
RA   Lim S.T., Mikolon D., Stupack D.G., Schlaepfer D.D.;
RT   "FERM control of FAK function: implications for cancer therapy.";
RL   Cell Cycle 7:2306-2314(2008).
RN   [58]
RP   REVIEW ON FUNCTION IN REGULATION OF RHO FAMILY GTPASE ACTIVITY.
RX   PubMed=19525103; DOI=10.1016/j.ceb.2009.05.006;
RA   Tomar A., Schlaepfer D.D.;
RT   "Focal adhesion kinase: switching between GAPs and GEFs in the regulation
RT   of cell motility.";
RL   Curr. Opin. Cell Biol. 21:676-683(2009).
RN   [59]
RP   REVIEW ON EXPRESSION IN CANCER, AND ROLE IN DISEASE.
RX   PubMed=19224453; DOI=10.14670/hh-24.503;
RA   Golubovskaya V.M., Kweh F.A., Cance W.G.;
RT   "Focal adhesion kinase and cancer.";
RL   Histol. Histopathol. 24:503-510(2009).
RN   [60]
RP   REVIEW ON FUNCTION IN REGULATION OF P53/TP53.
RX   PubMed=20515733; DOI=10.2741/3653;
RA   Golubovskaya V.M., Cance W.;
RT   "Focal adhesion kinase and p53 signal transduction pathways in cancer.";
RL   Front. Biosci. 15:901-912(2010).
RN   [61]
RP   REVIEW ON ROLE IN DEVELOPMENT.
RX   PubMed=20552554; DOI=10.14670/hh-25.1039;
RA   Chatzizacharias N.A., Kouraklis G.P., Theocharis S.E.;
RT   "The role of focal adhesion kinase in early development.";
RL   Histol. Histopathol. 25:1039-1055(2010).
RN   [62]
RP   REVIEW ON FUNCTION IN INTEGRIN SIGNALING AND ACTIVATION OF DOWNSTREAM
RP   SIGNALING PATHWAYS.
RX   PubMed=20101634; DOI=10.1002/iub.303;
RA   Guan J.L.;
RT   "Integrin signaling through FAK in the regulation of mammary stem cells and
RT   breast cancer.";
RL   IUBMB Life 62:268-276(2010).
RN   [63]
RP   FUNCTION, AND SIGNALING.
RX   PubMed=20332118; DOI=10.1242/jcs.045112;
RA   Schaller M.D.;
RT   "Cellular functions of FAK kinases: insight into molecular mechanisms and
RT   novel functions.";
RL   J. Cell Sci. 123:1007-1013(2010).
RN   [64]
RP   REVIEW ON FUNCTION; SUBUNIT; PHOSPHORYLATION; ACTIVITY REGULATION AND ROLE
RP   IN DISEASE.
RX   PubMed=21482413; DOI=10.1016/b978-0-12-386041-5.00005-4;
RA   Hall J.E., Fu W., Schaller M.D.;
RT   "Focal adhesion kinase: exploring Fak structure to gain insight into
RT   function.";
RL   Int. Rev. Cell Mol. Biol. 288:185-225(2011).
RN   [65]
RP   INTERACTION WITH MISP.
RX   PubMed=23509069; DOI=10.1083/jcb.201207050;
RA   Zhu M., Settele F., Kotak S., Sanchez-Pulido L., Ehret L., Ponting C.P.,
RA   Goenczy P., Hoffmann I.;
RT   "MISP is a novel Plk1 substrate required for proper spindle orientation and
RT   mitotic progression.";
RL   J. Cell Biol. 200:773-787(2013).
RN   [66]
RP   SUBUNIT.
RX   PubMed=29069646; DOI=10.1159/000484298;
RA   Rui Y.N., Xu Z., Fang X., Menezes M.R., Balzeau J., Niu A., Hagan J.P.,
RA   Kim D.H.;
RT   "The Intracranial Aneurysm Gene THSD1 Connects Endosome Dynamics to Nascent
RT   Focal Adhesion Assembly.";
RL   Cell. Physiol. Biochem. 43:2200-2211(2017).
RN   [67]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=31630787; DOI=10.1016/j.ajhg.2019.09.022;
RA   Wallmeier J., Frank D., Shoemark A., Noethe-Menchen T., Cindric S.,
RA   Olbrich H., Loges N.T., Aprea I., Dougherty G.W., Pennekamp P., Kaiser T.,
RA   Mitchison H.M., Hogg C., Carr S.B., Zariwala M.A., Ferkol T., Leigh M.W.,
RA   Davis S.D., Atkinson J., Dutcher S.K., Knowles M.R., Thiele H.,
RA   Altmueller J., Krenz H., Woeste M., Brentrup A., Ahrens F., Vogelberg C.,
RA   Morris-Rosendahl D.J., Omran H.;
RT   "De Novo Mutations in FOXJ1 Result in a Motile Ciliopathy with
RT   Hydrocephalus and Randomization of Left/Right Body Asymmetry.";
RL   Am. J. Hum. Genet. 105:1030-1039(2019).
RN   [68]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 891-1052, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=12005431; DOI=10.1016/s0969-2126(02)00717-7;
RA   Arold S.T., Hoellerer M.K., Noble M.E.;
RT   "The structural basis of localization and signaling by the focal adhesion
RT   targeting domain.";
RL   Structure 10:319-327(2002).
RN   [69]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 411-686 IN COMPLEX WITH ATP.
RX   PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases
RT   from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 892-1052 IN COMPLEX WITH PXN, AND
RP   INTERACTION WITH PXN.
RX   PubMed=14527389; DOI=10.1016/j.str.2003.08.010;
RA   Hoellerer M.K., Noble M.E., Labesse G., Campbell I.D., Werner J.M.,
RA   Arold S.T.;
RT   "Molecular recognition of paxillin LD motifs by the focal adhesion
RT   targeting domain.";
RL   Structure 11:1207-1217(2003).
RN   [71]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 414-689 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=18339875; DOI=10.1158/0008-5472.can-07-5155;
RA   Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C.,
RA   Richter D., Emerson E., Lin J., Kath J., Coleman K., Yao L.,
RA   Martinez-Alsina L., Lorenzen M., Berliner M., Luzzio M., Patel N.,
RA   Schmitt E., LaGreca S., Jani J., Wessel M., Marr E., Griffor M., Vajdos F.;
RT   "Antitumor activity and pharmacology of a selective focal adhesion kinase
RT   inhibitor, PF-562,271.";
RL   Cancer Res. 68:1935-1944(2008).
RN   [72]
RP   X-RAY CRYSTALLOGRAPHY (2.82 ANGSTROMS) OF 891-1052 IN COMPLEX WITH CD4,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CD4.
RX   PubMed=18078954; DOI=10.1016/j.jmb.2007.11.040;
RA   Garron M.L., Arthos J., Guichou J.F., McNally J., Cicala C., Arold S.T.;
RT   "Structural basis for the interaction between focal adhesion kinase and
RT   CD4.";
RL   J. Mol. Biol. 375:1320-1328(2008).
RN   [73]
RP   VARIANTS [LARGE SCALE ANALYSIS] PRO-292; GLN-292; ALA-793; GLU-1030 AND
RP   GLU-1044.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein-tyrosine kinase that plays an essential
CC       role in regulating cell migration, adhesion, spreading, reorganization
CC       of the actin cytoskeleton, formation and disassembly of focal adhesions
CC       and cell protrusions, cell cycle progression, cell proliferation and
CC       apoptosis. Required for early embryonic development and placenta
CC       development. Required for embryonic angiogenesis, normal cardiomyocyte
CC       migration and proliferation, and normal heart development. Regulates
CC       axon growth and neuronal cell migration, axon branching and synapse
CC       formation; required for normal development of the nervous system. Plays
CC       a role in osteogenesis and differentiation of osteoblasts. Functions in
CC       integrin signal transduction, but also in signaling downstream of
CC       numerous growth factor receptors, G-protein coupled receptors (GPCR),
CC       EPHA2, netrin receptors and LDL receptors. Forms multisubunit signaling
CC       complexes with SRC and SRC family members upon activation; this leads
CC       to the phosphorylation of additional tyrosine residues, creating
CC       binding sites for scaffold proteins, effectors and substrates.
CC       Regulates numerous signaling pathways. Promotes activation of
CC       phosphatidylinositol 3-kinase and the AKT1 signaling cascade. Promotes
CC       activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling
CC       cascade. Promotes localized and transient activation of guanine
CC       nucleotide exchange factors (GEFs) and GTPase-activating proteins
CC       (GAPs), and thereby modulates the activity of Rho family GTPases.
CC       Signaling via CAS family members mediates activation of RAC1.
CC       Phosphorylates NEDD9 following integrin stimulation (PubMed:9360983).
CC       Recruits the ubiquitin ligase MDM2 to P53/TP53 in the nucleus, and
CC       thereby regulates P53/TP53 activity, P53/TP53 ubiquitination and
CC       proteasomal degradation. Phosphorylates SRC; this increases SRC kinase
CC       activity. Phosphorylates ACTN1, ARHGEF7, GRB7, RET and WASL. Promotes
CC       phosphorylation of PXN and STAT1; most likely PXN and STAT1 are
CC       phosphorylated by a SRC family kinase that is recruited to
CC       autophosphorylated PTK2/FAK1, rather than by PTK2/FAK1 itself. Promotes
CC       phosphorylation of BCAR1; GIT2 and SHC1; this requires both SRC and
CC       PTK2/FAK1. Promotes phosphorylation of BMX and PIK3R1. Isoform 6 (FRNK)
CC       does not contain a kinase domain and inhibits PTK2/FAK1 phosphorylation
CC       and signaling. Its enhanced expression can attenuate the nuclear
CC       accumulation of LPXN and limit its ability to enhance serum response
CC       factor (SRF)-dependent gene transcription.
CC       {ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:11331870,
CC       ECO:0000269|PubMed:11980671, ECO:0000269|PubMed:15166238,
CC       ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:15895076,
CC       ECO:0000269|PubMed:16919435, ECO:0000269|PubMed:16927379,
CC       ECO:0000269|PubMed:17395594, ECO:0000269|PubMed:17431114,
CC       ECO:0000269|PubMed:17968709, ECO:0000269|PubMed:18006843,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:18256281,
CC       ECO:0000269|PubMed:18292575, ECO:0000269|PubMed:18497331,
CC       ECO:0000269|PubMed:18677107, ECO:0000269|PubMed:19138410,
CC       ECO:0000269|PubMed:19147981, ECO:0000269|PubMed:19224453,
CC       ECO:0000269|PubMed:20332118, ECO:0000269|PubMed:20495381,
CC       ECO:0000269|PubMed:21454698, ECO:0000269|PubMed:9360983}.
CC   -!- FUNCTION: [Isoform 6]: Isoform 6 (FRNK) does not contain a kinase
CC       domain and inhibits PTK2/FAK1 phosphorylation and signaling. Its
CC       enhanced expression can attenuate the nuclear accumulation of LPXN and
CC       limit its ability to enhance serum response factor (SRF)-dependent gene
CC       transcription. {ECO:0000269|PubMed:20109444}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:11331870,
CC         ECO:0000269|PubMed:18339875};
CC   -!- ACTIVITY REGULATION: Subject to autoinhibition, mediated by
CC       interactions between the FERM domain and the kinase domain. Activated
CC       by autophosphorylation at Tyr-397. This promotes interaction with SRC
CC       and phosphorylation at Tyr-576 and Tyr-577 in the kinase activation
CC       loop. Phosphorylation at Tyr-576 and Tyr-577 is required for maximal
CC       kinase activity. Inhibited by TAC544, TAE226, PF-573,228 and
CC       PF-562,271. {ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:17395594,
CC       ECO:0000269|PubMed:17431114, ECO:0000269|PubMed:18006843,
CC       ECO:0000269|PubMed:18677107, ECO:0000269|PubMed:20495381}.
CC   -!- SUBUNIT: Interacts (via first Pro-rich region) with CAS family members
CC       (via SH3 domain), including BCAR1, BCAR3, and CASS4. Interacts with
CC       NEDD9 (via SH3 domain) (PubMed:9360983). Interacts with GIT1. Interacts
CC       with SORBS1. Interacts with ARHGEF28. Interacts with SHB. Part of a
CC       complex composed of THSD1, PTK2/FAK1, TLN1 and VCL (PubMed:29069646).
CC       Interacts with PXN and TLN1. Interacts with STAT1. Interacts with DCC.
CC       Interacts with WASL. Interacts with ARHGEF7. Interacts with GRB2 and
CC       GRB7 (By similarity). Component of a complex that contains at least
CC       FER, CTTN and PTK2/FAK1. Interacts with BMX. Interacts with TGFB1I1.
CC       Interacts with STEAP4. Interacts with ZFYVE21. Interacts with ESR1.
CC       Interacts with PIK3R1 or PIK3R2. Interacts with SRC, FGR, FLT4 and RET.
CC       Interacts with EPHA2 in resting cells; activation of EPHA2 recruits
CC       PTPN11, leading to dephosphorylation of PTK2/FAK1 and dissociation of
CC       the complex. Interacts with EPHA1 (kinase activity-dependent).
CC       Interacts with CD4; this interaction requires the presence of HIV-1
CC       gp120. Interacts with PIAS1. Interacts with ARHGAP26 and SHC1.
CC       Interacts with RB1CC1; this inhibits PTK2/FAK1 activity and activation
CC       of downstream signaling pathways. Interacts with P53/TP53 and MDM2.
CC       Interacts with LPXN (via LD motif 3). Interacts with MISP. Interacts
CC       with CIB1 isoform 2. Interacts with CD36. Interacts with EMP2;
CC       regulates PTK2 activation and localization (PubMed:19494199). Interacts
CC       with DSCAM (By similarity). Interacts with AMBRA1 (By similarity).
CC       {ECO:0000250, ECO:0000250|UniProtKB:P34152,
CC       ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:11331870,
CC       ECO:0000269|PubMed:11980671, ECO:0000269|PubMed:12221124,
CC       ECO:0000269|PubMed:12387730, ECO:0000269|PubMed:12467573,
CC       ECO:0000269|PubMed:14527389, ECO:0000269|PubMed:15855171,
CC       ECO:0000269|PubMed:16452200, ECO:0000269|PubMed:18078954,
CC       ECO:0000269|PubMed:18256281, ECO:0000269|PubMed:18292575,
CC       ECO:0000269|PubMed:18339875, ECO:0000269|PubMed:18497331,
CC       ECO:0000269|PubMed:18657504, ECO:0000269|PubMed:19118217,
CC       ECO:0000269|PubMed:19339212, ECO:0000269|PubMed:19494199,
CC       ECO:0000269|PubMed:19787193, ECO:0000269|PubMed:19917054,
CC       ECO:0000269|PubMed:20037584, ECO:0000269|PubMed:20439989,
CC       ECO:0000269|PubMed:21454698, ECO:0000269|PubMed:23503467,
CC       ECO:0000269|PubMed:23509069, ECO:0000269|PubMed:29069646,
CC       ECO:0000269|PubMed:9360983, ECO:0000269|PubMed:9422762,
CC       ECO:0000269|PubMed:9756887}.
CC   -!- INTERACTION:
CC       Q05397; P56945: BCAR1; NbExp=2; IntAct=EBI-702142, EBI-702093;
CC       Q05397; P46108: CRK; NbExp=3; IntAct=EBI-702142, EBI-886;
CC       Q05397; P00533: EGFR; NbExp=7; IntAct=EBI-702142, EBI-297353;
CC       Q05397; P29317: EPHA2; NbExp=3; IntAct=EBI-702142, EBI-702104;
CC       Q05397; P06241: FYN; NbExp=3; IntAct=EBI-702142, EBI-515315;
CC       Q05397; P62993: GRB2; NbExp=4; IntAct=EBI-702142, EBI-401755;
CC       Q05397; Q14451: GRB7; NbExp=3; IntAct=EBI-702142, EBI-970191;
CC       Q05397; P08631-2: HCK; NbExp=2; IntAct=EBI-702142, EBI-9834454;
CC       Q05397; P16144: ITGB4; NbExp=7; IntAct=EBI-702142, EBI-948678;
CC       Q05397; Q92569: PIK3R3; NbExp=3; IntAct=EBI-702142, EBI-79893;
CC       Q05397; P25105: PTAFR; NbExp=2; IntAct=EBI-702142, EBI-3906092;
CC       Q05397; Q9H3S7: PTPN23; NbExp=4; IntAct=EBI-702142, EBI-724478;
CC       Q05397; P29350-3: PTPN6; NbExp=3; IntAct=EBI-702142, EBI-7399369;
CC       Q05397; Q9Y3E5: PTRH2; NbExp=2; IntAct=EBI-702142, EBI-1056751;
CC       Q05397; P49023: PXN; NbExp=18; IntAct=EBI-702142, EBI-702209;
CC       Q05397; Q9NP31: SH2D2A; NbExp=3; IntAct=EBI-702142, EBI-490630;
CC       Q05397; P12931: SRC; NbExp=9; IntAct=EBI-702142, EBI-621482;
CC       Q05397; Q96SB4: SRPK1; NbExp=2; IntAct=EBI-702142, EBI-539478;
CC       Q05397; P42224: STAT1; NbExp=3; IntAct=EBI-702142, EBI-1057697;
CC       Q05397; O43294: TGFB1I1; NbExp=4; IntAct=EBI-702142, EBI-1051449;
CC       Q05397; Q68CZ2: TNS3; NbExp=3; IntAct=EBI-702142, EBI-1220488;
CC       Q05397; P04637: TP53; NbExp=13; IntAct=EBI-702142, EBI-366083;
CC       Q05397; P07947: YES1; NbExp=2; IntAct=EBI-702142, EBI-515331;
CC       Q05397; Q824H6: CCA_00170; Xeno; NbExp=3; IntAct=EBI-702142, EBI-26494126;
CC       Q05397; P05480: Src; Xeno; NbExp=5; IntAct=EBI-702142, EBI-298680;
CC       Q05397; Q62219: Tgfb1i1; Xeno; NbExp=3; IntAct=EBI-702142, EBI-642844;
CC   -!- SUBCELLULAR LOCATION: Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:10655584, ECO:0000269|PubMed:15855171,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:18256281,
CC       ECO:0000269|PubMed:31630787}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q00944}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q00944}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q00944}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:15855171}. Cytoplasm, cell cortex. Cytoplasm,
CC       cytoskeleton {ECO:0000250|UniProtKB:O35346}. Cytoplasm, cytoskeleton,
CC       microtubule organizing center, centrosome {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:15855171, ECO:0000269|PubMed:18206965}. Cytoplasm,
CC       cytoskeleton, cilium basal body {ECO:0000269|PubMed:31630787}.
CC       Cytoplasm {ECO:0000269|PubMed:15855171, ECO:0000269|PubMed:18078954,
CC       ECO:0000269|PubMed:18206965, ECO:0000269|PubMed:18256281}.
CC       Note=Constituent of focal adhesions. Detected at microtubules.
CC       {ECO:0000250|UniProtKB:P34152}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=7;
CC       Name=1;
CC         IsoId=Q05397-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q05397-2; Sequence=VSP_004967, VSP_004968, VSP_004969,
CC                                  VSP_004970;
CC       Name=3;
CC         IsoId=Q05397-3; Sequence=VSP_004967, VSP_004968, VSP_004969,
CC                                  VSP_004973, VSP_004974;
CC       Name=4;
CC         IsoId=Q05397-4; Sequence=VSP_004967, VSP_004968, VSP_004969,
CC                                  VSP_004971, VSP_004972;
CC       Name=5;
CC         IsoId=Q05397-5; Sequence=VSP_042169, VSP_042170;
CC       Name=6; Synonyms=FRNK;
CC         IsoId=Q05397-6; Sequence=VSP_042168;
CC       Name=7;
CC         IsoId=Q05397-7; Sequence=VSP_057268;
CC   -!- TISSUE SPECIFICITY: Detected in B and T-lymphocytes. Isoform 1 and
CC       isoform 6 are detected in lung fibroblasts (at protein level).
CC       Ubiquitous. Expressed in epithelial cells (at protein level)
CC       (PubMed:31630787). {ECO:0000269|PubMed:20109444,
CC       ECO:0000269|PubMed:31630787, ECO:0000269|PubMed:7692878,
CC       ECO:0000269|PubMed:8247543, ECO:0000269|PubMed:8422239}.
CC   -!- DEVELOPMENTAL STAGE: [Isoform 6]: Detected in cultured cells,
CC       immediately after seeding and before formation of focal adhesions (at
CC       protein level). {ECO:0000269|PubMed:20109444}.
CC   -!- DOMAIN: The Pro-rich regions interact with the SH3 domain of CAS family
CC       members, such as BCAR1 and NEDD9, and with the GTPase activating
CC       protein ARHGAP26.
CC   -!- DOMAIN: The C-terminal region is the site of focal adhesion targeting
CC       (FAT) sequence which mediates the localization of FAK1 to focal
CC       adhesions.
CC   -!- PTM: Phosphorylated on tyrosine residues upon activation, e.g. upon
CC       integrin signaling. Tyr-397 is the major autophosphorylation site, but
CC       other kinases can also phosphorylate this residue. Phosphorylation at
CC       Tyr-397 promotes interaction with SRC and SRC family members, leading
CC       to phosphorylation at Tyr-576, Tyr-577 and at additional tyrosine
CC       residues. FGR promotes phosphorylation at Tyr-397 and Tyr-576. FER
CC       promotes phosphorylation at Tyr-577, Tyr-861 and Tyr-925, even when
CC       cells are not adherent. Tyr-397, Tyr-576 and Ser-722 are phosphorylated
CC       only when cells are adherent. Phosphorylation at Tyr-397 is important
CC       for interaction with BMX, PIK3R1 and SHC1. Phosphorylation at Tyr-925
CC       is important for interaction with GRB2. Dephosphorylated by PTPN11;
CC       PTPN11 is recruited to PTK2 via EPHA2 (tyrosine phosphorylated).
CC       Microtubule-induced dephosphorylation at Tyr-397 is crucial for the
CC       induction of focal adhesion disassembly; this dephosphorylation could
CC       be catalyzed by PTPN11 and regulated by ZFYVE21. Phosphorylation on
CC       tyrosine residues is enhanced by NTN1 (By similarity).
CC       {ECO:0000250|UniProtKB:P34152, ECO:0000269|PubMed:12387730,
CC       ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:17395594,
CC       ECO:0000269|PubMed:17431114, ECO:0000269|PubMed:18006843,
CC       ECO:0000269|PubMed:19339212, ECO:0000269|PubMed:21454698}.
CC   -!- PTM: Sumoylated; this enhances autophosphorylation. {ECO:0000250}.
CC   -!- DISEASE: Note=Aberrant PTK2/FAK1 expression may play a role in cancer
CC       cell proliferation, migration and invasion, in tumor formation and
CC       metastasis. PTK2/FAK1 overexpression is seen in many types of cancer.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative promoter usage.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. FAK subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PTK2ID41898ch8q24.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13616; AAA58469.1; -; mRNA.
DR   EMBL; L05186; AAA35819.1; -; mRNA.
DR   EMBL; AK304356; BAG65198.1; -; mRNA.
DR   EMBL; AC067931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC100860; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105009; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC105235; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458878; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458882; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035404; AAH35404.1; -; mRNA.
DR   CCDS; CCDS56557.1; -. [Q05397-5]
DR   CCDS; CCDS6381.1; -. [Q05397-1]
DR   PIR; I53012; I53012.
DR   PIR; PC1225; PC1225.
DR   RefSeq; NP_001186578.1; NM_001199649.1. [Q05397-5]
DR   RefSeq; NP_722560.1; NM_153831.3. [Q05397-1]
DR   RefSeq; XP_016869162.1; XM_017013673.1.
DR   PDB; 1K04; X-ray; 1.95 A; A=891-1052.
DR   PDB; 1K05; X-ray; 2.90 A; A/B/C=891-1052.
DR   PDB; 1MP8; X-ray; 1.60 A; A=411-686.
DR   PDB; 1OW6; X-ray; 2.35 A; A/B/C=892-1052.
DR   PDB; 1OW7; X-ray; 2.60 A; A/B/C=892-1052.
DR   PDB; 1OW8; X-ray; 2.85 A; A/B/C=892-1052.
DR   PDB; 2ETM; X-ray; 2.30 A; A/B=411-689.
DR   PDB; 2IJM; X-ray; 2.19 A; A/B=411-689.
DR   PDB; 3B71; X-ray; 2.82 A; A/B/C=891-1052.
DR   PDB; 3BZ3; X-ray; 2.20 A; A=414-689.
DR   PDB; 3PXK; X-ray; 1.79 A; A/B=411-689.
DR   PDB; 3S9O; X-ray; 2.60 A; A/B/C=891-1052.
DR   PDB; 4EBV; X-ray; 1.67 A; A=411-686.
DR   PDB; 4EBW; X-ray; 2.65 A; A=411-686.
DR   PDB; 4GU6; X-ray; 1.95 A; A/B=411-689.
DR   PDB; 4GU9; X-ray; 2.40 A; A/B=410-686.
DR   PDB; 4I4E; X-ray; 1.55 A; A=411-686.
DR   PDB; 4I4F; X-ray; 1.75 A; A=411-686.
DR   PDB; 4K8A; X-ray; 2.91 A; A/B=410-686.
DR   PDB; 4K9Y; X-ray; 2.00 A; A=410-686.
DR   PDB; 4KAB; X-ray; 2.71 A; A/B=410-686.
DR   PDB; 4KAO; X-ray; 2.39 A; A/B=410-689.
DR   PDB; 4NY0; X-ray; 2.80 A; A/B/C/D=31-405.
DR   PDB; 4Q9S; X-ray; 2.07 A; A=411-686.
DR   PDB; 6I8Z; X-ray; 1.99 A; A=411-689.
DR   PDB; 6LES; X-ray; 2.00 A; A/B/X/Y=805-832.
DR   PDB; 6PW8; X-ray; 1.95 A; A=922-1047.
DR   PDB; 6YOJ; X-ray; 1.36 A; A=411-689.
DR   PDB; 6YQ1; X-ray; 1.78 A; A/B/C/D=411-689.
DR   PDB; 6YR9; X-ray; 1.93 A; A/B/C/D=411-689.
DR   PDB; 6YT6; X-ray; 1.54 A; A/B=411-689.
DR   PDB; 6YVS; X-ray; 1.81 A; A/B/C/D=411-689.
DR   PDB; 6YVY; X-ray; 1.92 A; A/B/C/D=411-689.
DR   PDB; 6YXV; X-ray; 2.30 A; A/B/C/D=411-689.
DR   PDB; 7PI4; X-ray; 2.24 A; DDD=415-687.
DR   PDBsum; 1K04; -.
DR   PDBsum; 1K05; -.
DR   PDBsum; 1MP8; -.
DR   PDBsum; 1OW6; -.
DR   PDBsum; 1OW7; -.
DR   PDBsum; 1OW8; -.
DR   PDBsum; 2ETM; -.
DR   PDBsum; 2IJM; -.
DR   PDBsum; 3B71; -.
DR   PDBsum; 3BZ3; -.
DR   PDBsum; 3PXK; -.
DR   PDBsum; 3S9O; -.
DR   PDBsum; 4EBV; -.
DR   PDBsum; 4EBW; -.
DR   PDBsum; 4GU6; -.
DR   PDBsum; 4GU9; -.
DR   PDBsum; 4I4E; -.
DR   PDBsum; 4I4F; -.
DR   PDBsum; 4K8A; -.
DR   PDBsum; 4K9Y; -.
DR   PDBsum; 4KAB; -.
DR   PDBsum; 4KAO; -.
DR   PDBsum; 4NY0; -.
DR   PDBsum; 4Q9S; -.
DR   PDBsum; 6I8Z; -.
DR   PDBsum; 6LES; -.
DR   PDBsum; 6PW8; -.
DR   PDBsum; 6YOJ; -.
DR   PDBsum; 6YQ1; -.
DR   PDBsum; 6YR9; -.
DR   PDBsum; 6YT6; -.
DR   PDBsum; 6YVS; -.
DR   PDBsum; 6YVY; -.
DR   PDBsum; 6YXV; -.
DR   PDBsum; 7PI4; -.
DR   AlphaFoldDB; Q05397; -.
DR   SMR; Q05397; -.
DR   BioGRID; 111719; 222.
DR   CORUM; Q05397; -.
DR   ELM; Q05397; -.
DR   IntAct; Q05397; 137.
DR   MINT; Q05397; -.
DR   STRING; 9606.ENSP00000341189; -.
DR   BindingDB; Q05397; -.
DR   ChEMBL; CHEMBL2695; -.
DR   DrugBank; DB07460; 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE.
DR   DrugBank; DB07248; 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE.
DR   DrugBank; DB06423; Endostatin.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q05397; -.
DR   GuidetoPHARMACOLOGY; 2180; -.
DR   CarbonylDB; Q05397; -.
DR   GlyGen; Q05397; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q05397; -.
DR   PhosphoSitePlus; Q05397; -.
DR   BioMuta; PTK2; -.
DR   DMDM; 3183518; -.
DR   CPTAC; CPTAC-1785; -.
DR   EPD; Q05397; -.
DR   jPOST; Q05397; -.
DR   MassIVE; Q05397; -.
DR   MaxQB; Q05397; -.
DR   PaxDb; Q05397; -.
DR   PeptideAtlas; Q05397; -.
DR   PRIDE; Q05397; -.
DR   ProteomicsDB; 58320; -. [Q05397-1]
DR   ProteomicsDB; 58321; -. [Q05397-2]
DR   ProteomicsDB; 58322; -. [Q05397-3]
DR   ProteomicsDB; 58323; -. [Q05397-4]
DR   ProteomicsDB; 58324; -. [Q05397-5]
DR   ProteomicsDB; 58325; -. [Q05397-6]
DR   ProteomicsDB; 71210; -.
DR   Antibodypedia; 725; 2888 antibodies from 47 providers.
DR   DNASU; 5747; -.
DR   Ensembl; ENST00000340930.7; ENSP00000341189.3; ENSG00000169398.20. [Q05397-5]
DR   Ensembl; ENST00000395218.3; ENSP00000378644.3; ENSG00000169398.20. [Q05397-7]
DR   Ensembl; ENST00000521059.5; ENSP00000429474.1; ENSG00000169398.20. [Q05397-1]
DR   Ensembl; ENST00000522684.5; ENSP00000429911.1; ENSG00000169398.20. [Q05397-1]
DR   GeneID; 5747; -.
DR   KEGG; hsa:5747; -.
DR   UCSC; uc003yvu.4; human. [Q05397-1]
DR   CTD; 5747; -.
DR   DisGeNET; 5747; -.
DR   GeneCards; PTK2; -.
DR   HGNC; HGNC:9611; PTK2.
DR   HPA; ENSG00000169398; Low tissue specificity.
DR   MIM; 600758; gene.
DR   neXtProt; NX_Q05397; -.
DR   OpenTargets; ENSG00000169398; -.
DR   PharmGKB; PA33955; -.
DR   VEuPathDB; HostDB:ENSG00000169398; -.
DR   eggNOG; KOG4257; Eukaryota.
DR   GeneTree; ENSGT00940000155113; -.
DR   HOGENOM; CLU_002646_0_0_1; -.
DR   InParanoid; Q05397; -.
DR   OMA; ELECMFK; -.
DR   OrthoDB; 43729at2759; -.
DR   PhylomeDB; Q05397; -.
DR   TreeFam; TF316643; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q05397; -.
DR   Reactome; R-HSA-111465; Apoptotic cleavage of cellular proteins.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-354192; Integrin signaling.
DR   Reactome; R-HSA-354194; GRB2:SOS provides linkage to MAPK signaling for Integrins.
DR   Reactome; R-HSA-372708; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; R-HSA-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-HSA-391160; Signal regulatory protein family interactions.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-8874081; MET activates PTK2 signaling.
DR   Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling.
DR   Reactome; R-HSA-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   SignaLink; Q05397; -.
DR   SIGNOR; Q05397; -.
DR   BioGRID-ORCS; 5747; 398 hits in 1128 CRISPR screens.
DR   ChiTaRS; PTK2; human.
DR   EvolutionaryTrace; Q05397; -.
DR   GeneWiki; PTK2; -.
DR   GenomeRNAi; 5747; -.
DR   Pharos; Q05397; Tclin.
DR   PRO; PR:Q05397; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q05397; protein.
DR   Bgee; ENSG00000169398; Expressed in corpus callosum and 208 other tissues.
DR   ExpressionAtlas; Q05397; baseline and differential.
DR   Genevisible; Q05397; HS.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0036064; C:ciliary basal body; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043197; C:dendritic spine; IBA:GO_Central.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001725; C:stress fiber; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005178; F:integrin binding; IPI:ARUK-UCL.
DR   GO; GO:0008432; F:JUN kinase binding; IDA:BHF-UCL.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; TAS:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:0048870; P:cell motility; TAS:UniProtKB.
DR   GO; GO:0035995; P:detection of muscle stretch; TAS:BHF-UCL.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0030010; P:establishment of cell polarity; TAS:UniProtKB.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0003007; P:heart morphogenesis; TAS:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IDA:BHF-UCL.
DR   GO; GO:0038007; P:netrin-activated signaling pathway; TAS:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0001890; P:placenta development; TAS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IGI:BHF-UCL.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IGI:BHF-UCL.
DR   GO; GO:0010763; P:positive regulation of fibroblast migration; IDA:ARUK-UCL.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IGI:ARUK-UCL.
DR   GO; GO:0120041; P:positive regulation of macrophage proliferation; IGI:ARUK-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0090303; P:positive regulation of wound healing; IDA:ARUK-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IBA:GO_Central.
DR   GO; GO:0065008; P:regulation of biological quality; IEA:UniProt.
DR   GO; GO:0030155; P:regulation of cell adhesion; IBA:GO_Central.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0010594; P:regulation of endothelial cell migration; TAS:UniProtKB.
DR   GO; GO:0010632; P:regulation of epithelial cell migration; IGI:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IGI:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; TAS:UniProtKB.
DR   GO; GO:0045667; P:regulation of osteoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IGI:UniProtKB.
DR   GO; GO:1900024; P:regulation of substrate adhesion-dependent cell spreading; IGI:UniProtKB.
DR   GO; GO:0007172; P:signal complex assembly; IEA:InterPro.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   CDD; cd14473; FERM_B-lobe; 1.
DR   CDD; cd13190; FERM_C_FAK1; 1.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR041390; FADK_N.
DR   InterPro; IPR041784; FAK1/PYK2_FERM_C.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_sf.
DR   InterPro; IPR035963; FERM_2.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR036137; Focal_adhe_kin_target_dom_sf.
DR   InterPro; IPR005189; Focal_adhesion_kin_target_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF18038; FERM_N_2; 1.
DR   Pfam; PF03623; Focal_AT; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF68993; SSF68993; 1.
DR   PROSITE; PS00661; FERM_2; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative promoter usage;
KW   Alternative splicing; Angiogenesis; ATP-binding; Cell junction;
KW   Cell membrane; Cell projection; Cytoplasm; Cytoskeleton;
KW   Developmental protein; Direct protein sequencing; Isopeptide bond; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.6, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19413330"
FT   CHAIN           2..1052
FT                   /note="Focal adhesion kinase 1"
FT                   /id="PRO_0000088077"
FT   DOMAIN          35..355
FT                   /note="FERM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00084"
FT   DOMAIN          422..680
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..27
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          684..734
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          707..1052
FT                   /note="Interaction with TGFB1I1"
FT   REGION          839..922
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          912..1052
FT                   /note="Interaction with ARHGEF28"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        9..24
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        866..880
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        890..922
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        546
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         428..434
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:12467573"
FT   BINDING         454
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:12467573"
FT   BINDING         500..502
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:12467573"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.6, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19413330"
FT   MOD_RES         5
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         13
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         29
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         54
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P34152"
FT   MOD_RES         397
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12387730,
FT                   ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:17395594,
FT                   ECO:0000269|PubMed:17431114, ECO:0000269|PubMed:18006843,
FT                   ECO:0000269|PubMed:19339212, ECO:0007744|PubMed:19369195"
FT   MOD_RES         407
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:12387730,
FT                   ECO:0000269|PubMed:15561106"
FT   MOD_RES         570
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         576
FT                   /note="Phosphotyrosine; by RET and SRC"
FT                   /evidence="ECO:0000269|PubMed:15561106,
FT                   ECO:0000269|PubMed:19339212, ECO:0000269|PubMed:21454698"
FT   MOD_RES         577
FT                   /note="Phosphotyrosine; by RET and SRC"
FT                   /evidence="ECO:0000269|PubMed:12387730,
FT                   ECO:0000269|PubMed:19339212, ECO:0000269|PubMed:21454698"
FT   MOD_RES         580
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         722
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:19339212"
FT   MOD_RES         732
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000250|UniProtKB:P34152"
FT   MOD_RES         843
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         861
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:12387730,
FT                   ECO:0000269|PubMed:18006843, ECO:0000269|PubMed:19339212"
FT   MOD_RES         887
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         910
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         914
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         925
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:12387730,
FT                   ECO:0000269|PubMed:19339212"
FT   CROSSLNK        152
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..692
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042168"
FT   VAR_SEQ         1..181
FT                   /note="Missing (in isoform 2, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004967"
FT   VAR_SEQ         182..189
FT                   /note="EMRGNALE -> MSDYWVVG (in isoform 2, isoform 3 and
FT                   isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004968"
FT   VAR_SEQ         472
FT                   /note="A -> ACHYTSLHWNWCRYISDPNVDACPDPRNAE (in isoform 2,
FT                   isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004969"
FT   VAR_SEQ         579..583
FT                   /note="ASKGK -> GKKSG (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004971"
FT   VAR_SEQ         584..1052
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004972"
FT   VAR_SEQ         677..706
FT                   /note="STILEEEKAQQEERMRMESRRQATVSWDSG -> FQNPAQMLPASGRLPNQP
FT                   CPERENYSFATF (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004973"
FT   VAR_SEQ         707..1052
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004974"
FT   VAR_SEQ         744..789
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_057268"
FT   VAR_SEQ         834..854
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8422239"
FT                   /id="VSP_004970"
FT   VAR_SEQ         868
FT                   /note="D -> GKEEKNWAERN (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042169"
FT   VAR_SEQ         903
FT                   /note="K -> KPWR (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042170"
FT   VARIANT         292
FT                   /note="H -> P"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041682"
FT   VARIANT         292
FT                   /note="H -> Q"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041683"
FT   VARIANT         793
FT                   /note="V -> A (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041684"
FT   VARIANT         1030
FT                   /note="D -> E"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041685"
FT   VARIANT         1044
FT                   /note="K -> E (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041686"
FT   MUTAGEN         397
FT                   /note="Y->F: Abolishes autophosphorylation. Abolishes
FT                   interaction with SRC and activation of BMX. Reduces
FT                   phosphorylation of NEDD9."
FT                   /evidence="ECO:0000269|PubMed:11331870,
FT                   ECO:0000269|PubMed:9360983"
FT   MUTAGEN         928
FT                   /note="V->G: Loss of interaction with TGFB1I1."
FT                   /evidence="ECO:0000269|PubMed:9756887"
FT   MUTAGEN         1034
FT                   /note="L->S: Loss of interaction with TGFB1I1."
FT                   /evidence="ECO:0000269|PubMed:9756887"
FT   CONFLICT        184
FT                   /note="R -> L (in Ref. 3; BAG65198)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        211
FT                   /note="L -> I (in Ref. 3; BAG65198)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        778
FT                   /note="P -> S (in Ref. 2; AAA35819)"
FT                   /evidence="ECO:0000305"
FT   STRAND          35..40
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           49..51
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          53..58
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           64..73
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   TURN            74..76
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           80..82
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          83..89
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          95..98
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           104..114
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           117..119
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          120..126
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           133..137
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           141..158
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           165..179
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           185..187
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          188..190
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           191..194
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           197..201
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   TURN            204..206
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           209..214
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   TURN            217..219
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           220..228
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           229..231
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           236..247
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           248..250
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          256..262
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          264..266
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          268..275
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   TURN            276..278
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          279..283
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          290..294
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           296..298
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          299..306
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          308..311
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          314..320
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   STRAND          327..333
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           334..351
FT                   /evidence="ECO:0007829|PDB:4NY0"
FT   HELIX           413..415
FT                   /evidence="ECO:0007829|PDB:4EBV"
FT   HELIX           419..421
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          422..431
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          434..441
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          444..446
FT                   /evidence="ECO:0007829|PDB:6YVY"
FT   STRAND          449..455
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   TURN            457..460
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           462..476
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          486..490
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          492..494
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          496..500
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           507..513
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   TURN            514..517
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           520..539
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           549..551
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          552..556
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          559..562
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           565..568
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           570..573
FT                   /evidence="ECO:0007829|PDB:4GU6"
FT   HELIX           574..576
FT                   /evidence="ECO:0007829|PDB:4GU6"
FT   HELIX           586..588
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           591..596
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           601..616
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   TURN            617..619
FT                   /evidence="ECO:0007829|PDB:4EBV"
FT   TURN            622..625
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           628..636
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           649..658
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           663..665
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   HELIX           669..685
FT                   /evidence="ECO:0007829|PDB:6YOJ"
FT   STRAND          915..917
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           923..942
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           947..949
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           950..971
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           972..974
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           977..979
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           980..1006
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   TURN            1007..1009
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   STRAND          1010..1012
FT                   /evidence="ECO:0007829|PDB:1K04"
FT   HELIX           1013..1045
FT                   /evidence="ECO:0007829|PDB:1K04"
SQ   SEQUENCE   1052 AA;  119233 MW;  D8A4C15138AB0243 CRC64;
     MAAAYLDPNL NHTPNSSTKT HLGTGMERSP GAMERVLKVF HYFESNSEPT TWASIIRHGD
     ATDVRGIIQK IVDSHKVKHV ACYGFRLSHL RSEEVHWLHV DMGVSSVREK YELAHPPEEW
     KYELRIRYLP KGFLNQFTED KPTLNFFYQQ VKSDYMLEIA DQVDQEIALK LGCLEIRRSY
     WEMRGNALEK KSNYEVLEKD VGLKRFFPKS LLDSVKAKTL RKLIQQTFRQ FANLNREESI
     LKFFEILSPV YRFDKECFKC ALGSSWIISV ELAIGPEEGI SYLTDKGCNP THLADFTQVQ
     TIQYSNSEDK DRKGMLQLKI AGAPEPLTVT APSLTIAENM ADLIDGYCRL VNGTSQSFII
     RPQKEGERAL PSIPKLANSE KQGMRTHAVS VSETDDYAEI IDEEDTYTMP STRDYEIQRE
     RIELGRCIGE GQFGDVHQGI YMSPENPALA VAIKTCKNCT SDSVREKFLQ EALTMRQFDH
     PHIVKLIGVI TENPVWIIME LCTLGELRSF LQVRKYSLDL ASLILYAYQL STALAYLESK
     RFVHRDIAAR NVLVSSNDCV KLGDFGLSRY MEDSTYYKAS KGKLPIKWMA PESINFRRFT
     SASDVWMFGV CMWEILMHGV KPFQGVKNND VIGRIENGER LPMPPNCPPT LYSLMTKCWA
     YDPSRRPRFT ELKAQLSTIL EEEKAQQEER MRMESRRQAT VSWDSGGSDE APPKPSRPGY
     PSPRSSEGFY PSPQHMVQTN HYQVSGYPGS HGITAMAGSI YPGQASLLDQ TDSWNHRPQE
     IAMWQPNVED STVLDLRGIG QVLPTHLMEE RLIRQQQEME EDQRWLEKEE RFLKPDVRLS
     RGSIDREDGS LQGPIGNQHI YQPVGKPDPA APPKKPPRPG APGHLGSLAS LSSPADSYNE
     GVKLQPQEIS PPPTANLDRS NDKVYENVTG LVKAVIEMSS KIQPAPPEEY VPMVKEVGLA
     LRTLLATVDE TIPLLPASTH REIEMAQKLL NSDLGELINK MKLAQQYVMT SLQQEYKKQM
     LTAAHALAVD AKNLLDVIDQ ARLKMLGQTR PH
//
